Genomic Characteristics of Leiomyosarcoma: An AACR Project GENIE Study
Henna Ali1, Cinthiya Chander1, Elijah Torbenson1
1Creighton University School of Medicine, Omaha, NE, U.S.A.
Anticancer Research
|June 29, 2026
Summary
This study reveals frequent genetic alterations in TP53, RB1, and ATRX in leiomyosarcoma. It also suggests potential roles for IGF2 and AXIN1 in metastatic leiomyosarcoma progression.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Leiomyosarcoma is a rare, aggressive smooth muscle tumor with poor outcomes.
- Limited treatment options necessitate better understanding of tumor biology.
- Prior studies were constrained by small sample sizes and restricted gene analyses.
Purpose of the Study:
- To perform large-scale molecular characterization of leiomyosarcoma.
- To identify clinicogenomic features using a public dataset.
- To support precision oncology approaches for leiomyosarcoma.
Main Methods:
- Analysis of 1,017 tumor samples from 957 patients.
- Evaluation of demographic patterns, somatic mutations, and copy number alterations.
- Assessment of genomic co-occurrence and exclusivity in primary and metastatic disease.
Main Results:
- TP53 (50.3%), RB1 (17.9%), and ATRX (15.9%) were the most frequently altered genes.
- Recurrent copy number alterations included RB1 homozygous deletion (24.4%) and TP53 homozygous deletion (15.5%).
- Metastatic samples showed enrichment of IGF2 and AXIN1 alterations, unlike primary tumors.
Conclusions:
- Recurrent alterations in TP53, RB1, and ATRX are highlighted.
- Potential roles for IGF2 and AXIN1 in leiomyosarcoma metastasis require further investigation.
- Findings contribute to understanding leiomyosarcoma biology for precision oncology.
